

State of Oklahoma  
SoonerCare  
Retevmo<sup>®</sup> (Selpercatinib) Prior Authorization Form

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

### Drug Information

Pharmacy Billing (NDC: \_\_\_\_\_) Start Date (or date of next dose): \_\_\_\_\_

Dose: \_\_\_\_\_ Regimen: \_\_\_\_\_

### Billing Provider Information

Pharmacy NPI: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_

Pharmacy Phone: \_\_\_\_\_ Pharmacy Fax: \_\_\_\_\_

### Prescriber Information

Prescriber NPI: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_

Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_ Specialty: \_\_\_\_\_

### Criteria

#### For Initial Authorization:

#### 1. Please indicate the diagnosis and information:

**Non-Small Cell Lung Cancer (NSCLC)**

- A. Is diagnosis recurrent, advanced, or metastatic NSCLC? Yes  No
- B. Is tumor rearranged during transfection (RET) fusion positive? Yes  No
- C. Will selpercatinib be used as a single-agent? Yes  No

**Thyroid Cancer**

- A. Will selpercatinib be used as a single-agent? Yes  No
- B. Is disease advanced or metastatic? Yes  No
- C. Is diagnosis RET-mutant medullary thyroid cancer requiring systemic therapy? Yes  No
- D. Is diagnosis RET fusion-positive thyroid cancer? Yes  No
- i. If yes, does member require systemic therapy? Yes  No
- ii. Is radioactive iodine appropriate for this member? Yes  No
- a. If appropriate, is member refractory to radioactive iodine? Yes  No

**Solid Tumor**

- A. Is diagnosis locally advanced or metastatic solid tumor? Yes  No
- B. Is tumor rearranged during transfection (RET) gene fusion? Yes  No
- C. Has disease progressed on or following prior systemic treatment, or are there no satisfactory alternative treatment options? Yes  No
- D. Will selpercatinib be used as a single agent? Yes  No

If answer is none of the above, please indicate diagnosis: \_\_\_\_\_

Additional Information: \_\_\_\_\_

(Page 1 of 2)

Fax completed prior authorization request form to  
**888-601-8461** or submit Electronic Prior Authorization  
through CoverMyMeds<sup>®</sup> or SureScripts.  
All requested data must be provided. Incomplete forms or  
forms without the chart notes will be returned. Pharmacy  
Coverage Guidelines are available at  
**AetnaBetterHealth.com/Oklahoma.**

#### CONFIDENTIALITY NOTICE

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*



State of Oklahoma  
SoonerCare

**Retevmo® (Selpercatinib) Prior Authorization Form**

**Member Name:** \_\_\_\_\_ **Date of Birth:** \_\_\_\_\_ **Member ID#:** \_\_\_\_\_

**For Continued Authorization:**

1. Date of last dose: \_\_\_\_\_
  2. Does member have any evidence of progressive disease while on selpercatinib? Yes  No
  3. Has the member experienced adverse drug reactions related to selpercatinib therapy? Yes  No
- If yes, please specify adverse reactions: \_\_\_\_\_

(Page 2 of 2)

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.**

*Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.*

<p>Fax completed prior authorization request form to <b>888-601-8461</b> or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at <b>AetnaBetterHealth.com/Oklahoma.</b></p>	<p style="text-align: center;"><u>CONFIDENTIALITY NOTICE</u></p> <p><i>This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.</i></p>
--	--